IL23A and psoriasis: A selective AHR agonist, tapinarof is currently being studied because this medicinal agent improves both psoriasis and AD in which different pathomechanisms operate (the TNF-α/IL-23/IL-17 axis in psoriasis and IL-4/IL-13 signaling in AD).